Presatovir

Drug Profile

Presatovir

Alternative Names: GS-5806

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Amines; Antivirals; Chlorophenols; Piperidines; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 01 Sep 2015 Gilead Sciences plans a phase II trial for Respiratory syncytial virus infections (In adults, In the elderly) in USA, Austria, Australia, Belgium, Canada, France, Germany and United Kingdom (NCT02534350)
  • 01 Jan 2015 Phase-II clinical trials in Respiratory syncytial virus infections (In adults, In the elderly) in France (PO) (NCT02254408)
  • 01 Jan 2015 Phase-II clinical trials in Respiratory syncytial virus infections (In adults, In the elderly) in USA (PO) (NCT02254408)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top